التفاصيل البيبلوغرافية
| العنوان: |
A new target in multiple myeloma? TAK1 blocker boosts chemo's cancer-killing power in preclinical study. |
| المؤلفون: |
Weintraub, Arlene (AUTHOR) |
| المصدر: |
FierceBiotech. 10/18/2021, pN.PAG-N.PAG. 1p. |
| مصطلحات موضوعية: |
MULTIPLE myeloma, PROTEIN kinases, DRUG resistance, CD38 antigen |
| مصطلحات جغرافية: |
NORWAY |
| الشركة/الكيان: |
GLAXOSMITHKLINE |
| مستخلص: |
Several new therapies have been approved in recent years to treat multiple myeloma, but drug resistance is a common problem. Now, a team of Norwegian researchers has preliminary evidence that targeting a protein kinase called TAK1 could restore the power of chemotherapy to attack multiple myeloma cells. [ABSTRACT FROM AUTHOR] |
|
Copyright of FierceBiotech is the property of Questex Media Group and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Business Source Index |
